151 related articles for article (PubMed ID: 10609697)
1. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group.
Kittner B
Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697
[TBL] [Abstract][Full Text] [Related]
2. Classification of vascular dementia in the Cardiovascular Health Study Cognition Study.
Lopez OL; Kuller LH; Becker JT; Jagust WJ; DeKosky ST; Fitzpatrick A; Breitner J; Lyketsos C; Kawas C; Carlson M
Neurology; 2005 May; 64(9):1539-47. PubMed ID: 15883314
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia.
Purandare N; Voshaar RC; Morris J; Byrne JE; Wren J; Heller RF; McCollum CN; Burns A
Biol Psychiatry; 2007 Aug; 62(4):339-44. PubMed ID: 17531959
[TBL] [Abstract][Full Text] [Related]
4. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.
Rother M; Erkinjuntti T; Roessner M; Kittner B; Marcusson J; Karlsson I
Dement Geriatr Cogn Disord; 1998 Jul; 9 Suppl 1():36-43. PubMed ID: 9716243
[TBL] [Abstract][Full Text] [Related]
5. Facts, myths, and controversies in vascular dementia.
Román GC
J Neurol Sci; 2004 Nov; 226(1-2):49-52. PubMed ID: 15537519
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of vascular dementia and Alzheimer's disease.
Román G
Int J Clin Pract Suppl; 2001 May; (120):9-13. PubMed ID: 11406927
[TBL] [Abstract][Full Text] [Related]
7. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
Marcusson J; Rother M; Kittner B; Rössner M; Smith RJ; Babic T; Folnegovic-Smalc V; Möller HJ; Labs KH
Dement Geriatr Cogn Disord; 1997; 8(5):320-8. PubMed ID: 9298634
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences.
Pohjasvaara T; Mäntylä R; Ylikoski R; Kaste M; Erkinjuntti T
Stroke; 2000 Dec; 31(12):2952-7. PubMed ID: 11108755
[TBL] [Abstract][Full Text] [Related]
9. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
Gauthier S; Ferris S
Int J Clin Pract Suppl; 2001 May; (120):29-39. PubMed ID: 11406924
[TBL] [Abstract][Full Text] [Related]
10. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs.
Pantoni L
J Neurol Sci; 2004 Nov; 226(1-2):67-70. PubMed ID: 15537523
[TBL] [Abstract][Full Text] [Related]
11. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia.
Pratt RD
J Neurol Sci; 2002 Nov; 203-204():57-65. PubMed ID: 12417358
[TBL] [Abstract][Full Text] [Related]
12. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
Passmore AP; Bayer AJ; Steinhagen-Thiessen E
J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
[TBL] [Abstract][Full Text] [Related]
13. Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients.
Chaves ML; Camozzato AL; Godinho C; Kochhann R; Schuh A; de Almeida VL; Kaye J
Alzheimer Dis Assoc Disord; 2007; 21(3):210-7. PubMed ID: 17804953
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of introducing propentofylline for the treatment of dementia in Sweden.
Wimo A; Witthaus E; Rother M; Winblad B
Clin Ther; 1998; 20(3):552-66; discussion 550-1. PubMed ID: 9663370
[TBL] [Abstract][Full Text] [Related]
15. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
16. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
17. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.
Mielke R; Möller HJ; Erkinjuntti T; Rosenkranz B; Rother M; Kittner B
Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S29-35. PubMed ID: 9769027
[TBL] [Abstract][Full Text] [Related]
18. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia.
Bastos-Leite AJ; van der Flier WM; van Straaten EC; Staekenborg SS; Scheltens P; Barkhof F
Stroke; 2007 Dec; 38(12):3182-5. PubMed ID: 17962598
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials in dementia with propentofylline.
Kittner B; Rössner M; Rother M
Ann N Y Acad Sci; 1997 Sep; 826():307-16. PubMed ID: 9329701
[TBL] [Abstract][Full Text] [Related]
20. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD.
Erkinjuntti T
Int J Clin Pract Suppl; 2001 May; (120):14-23. PubMed ID: 11406922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
